International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)
ID: 347525Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $125K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/347525

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-23-023.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)" aimed at supporting research on infectious diseases in resource-constrained countries. This initiative specifically targets organizations headquartered in low- and lower-middle-income economies, as classified by the World Bank, and encourages collaboration with U.S. institutions to enhance local scientific capabilities. The program anticipates funding approximately 7-8 awards totaling $1.36 million, with a maximum budget of $125,000 per year per project, and applications are due by 5:00 PM local time on August 1, 2025. Interested applicants can find more information and submission guidelines at the NIH Grants website or contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-AI-23-023-Full-Announcement.html
    RFA-AI-23-023.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID), has issued a funding opportunity announcement (FOA) titled "International Research in Infectious Diseases" (R01 Clinical Trial Not Allowed). This initiative aims to support research on infectious diseases in resource-constrained foreign countries, with a particular focus on low- and lower-middle-income economies as classified by the World Bank. Applicant organizations must be headquartered in these eligible countries. The FOA encourages collaboration with U.S. institutions and emphasizes capability building in local scientific communities. Applications are due by 5:00 PM local time, with funding anticipated in 2024 for about 7-8 awards totaling $1.36 million, with a maximum budget of $125,000 per year per project. Projects may focus on a variety of infectious diseases but cannot include clinical trials. The application process requires compliance with specific instructions outlined in the announcement, and registration with eRA Commons and Grants.gov is mandatory. The document concludes with details on submission, review, and funding processes to ensure high scientific merit in proposed projects.
    Similar Opportunities
    Global Infectious Disease Research Training Program (D43 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Global Infectious Disease Research Training Program (D43 Clinical Trial Optional), aimed at enhancing research capacity in low- and middle-income countries (LMICs) regarding infectious diseases. This program encourages collaborative applications from U.S. and LMIC institutions, focusing on critical areas such as neglected tropical diseases and co-infections in HIV patients, while excluding HIV/AIDS as a primary focus. Successful applicants will develop structured training curricula, mentorship pairings, and research skills relevant to local health priorities, with annual budgets capped at $230,000 for a maximum project period of five years. Interested parties should note that the application deadline is August 6, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research initiatives focused on HIV-associated non-communicable diseases (NCDs) at low- and middle-income country (LMIC) institutions through the R21 Clinical Trial Optional grant. This program aims to support locally relevant research that explores the relationship between HIV infection and the development of NCDs, enhance research capacity, and foster collaborative networks among researchers in LMICs and the U.S. The grant provides funding up to $275,000 over a two-year period, with a submission deadline of December 8, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Global Infectious Disease Research Administration Development Award for Low-and Middle-Income Country Institutions (G11 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Global Infectious Disease Research Administration Development Award (G11 Clinical Trial Not Allowed), aimed at enhancing the administrative capabilities of research institutions in low- and middle-income countries (LMICs) through advanced training in grants management. This funding opportunity invites eligible institutions to develop comprehensive plans that include a Research Grants Administration/Financial Management Plan, Staff Training Plan, and a Long-term Plan, with the goal of improving oversight and compliance with NIH funding policies. The initiative emphasizes capacity building in resource-limited settings, supporting travel for senior administrators to receive training from experienced U.S. institutions, with project budgets capped at $100,000 annually for a maximum period of two years. Interested applicants should submit their proposals by March 13, 2026, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-300.html.
    Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)" to stimulate research aligned with the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This initiative aims to support research on HIV-related comorbidities, gastrointestinal diseases, and metabolic disorders associated with HIV, encouraging applications from a diverse range of organizations, including higher education institutions and non-profits. With an estimated funding of $2 million for fiscal year 2025, the NIH plans to support 3 to 5 selected projects over a maximum project period of five years, with applications undergoing a rigorous peer review process. Interested applicants can find more information and submit their proposals through Grants.gov, with a submission deadline of January 7, 2025. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Innovation for HIV Vaccine Discovery (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Innovation for HIV Vaccine Discovery" (NOFO Number PAR-23-169) aimed at supporting high-risk, high-impact early discovery research focused on innovative vaccine approaches to prevent HIV acquisition and ongoing infection. This initiative emphasizes a Go/No-Go funding approach, requiring applicants to demonstrate measurable progress towards defined goals by the end of Year 2, with continued funding contingent upon meeting these criteria. The overall budget for this initiative is approximately $2 million for fiscal year 2024, with individual project budgets capped at $350,000 per year, and applications must be submitted via Grants.gov by August 2, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Co-infection and Cancer (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Co-infection and Cancer (R01 Clinical Trial Not Allowed)" aimed at enhancing the understanding of infection-related cancers, particularly the roles of co-infection in cancer development. This initiative encourages mechanistic and epidemiologic studies that explore how infections by multiple agents—both pathogenic and non-pathogenic—can influence cancer risk and progression, with a focus on known oncogenic agents, excluding HIV. Given the significant proportion of cancer cases linked to infectious agents, this research is crucial for developing novel prevention and treatment strategies. Interested applicants, including a variety of educational institutions and organizations, particularly those from underrepresented groups, must submit their applications by November 5, 2025, and can find further details and guidelines at the NIH website or contact NIH Grants Information at grantsinfo@nih.gov.
    Co-infection and Cancer (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Co-infection and Cancer (R21 Clinical Trial Not Allowed)" aimed at enhancing research on the mechanisms and epidemiology of co-infections in relation to cancer development. This grant seeks innovative proposals that investigate how co-infections, particularly those involving known oncogenic agents (excluding HIV), may influence carcinogenesis and contribute to cancer disparities among diverse populations. The maximum funding amount available for each application is $275,000 over a two-year period, with applications due by November 16, 2025. Eligible applicants include a wide range of institutions and organizations, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    NIAID Resource-Related Research Projects (R24 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Allergy and Infectious Diseases (NIAID), is offering a funding opportunity for investigator-initiated Resource-Related Research Projects (R24), specifically excluding clinical trials. This initiative aims to enhance existing high-priority research by supporting resources that provide critical data, materials, tools, or services beneficial to the scientific community, particularly in areas related to immunology and infectious diseases. Eligible applicants include a diverse range of institutions, such as higher education and nonprofit organizations, with proposals due by January 7, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-23-065.html.
    Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)." This initiative aims to encourage research into the role of inflammasomes in the neuropathology associated with HIV infection and substance use disorders, particularly focusing on their impact on neurocognitive disorders and immune function. The program seeks to bridge knowledge gaps in treatment and research by exploring how inflammasome activation is influenced by HIV and substance use, with the goal of translating findings into clinical applications. A total funding amount of $2 million is available to support up to four grants, with a submission deadline of February 13, 2024. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Trial Not Allowed)" aimed at supporting exploratory research into the neuroimmune connections related to HIV and substance use disorders. This initiative seeks to identify and characterize neuroimmune networks and communication pathways, as well as discover novel modulatory tools that can enhance understanding of the regulatory mechanisms contributing to the comorbidity of HIV and substance use disorders. The NIH intends to allocate up to $2 million to fund approximately six awards, with individual budgets not exceeding $275,000 over a two-year period. Interested applicants must submit their proposals by November 13, 2024, and can find additional information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.